Indaptus shares jump 20% premarket after securing $6 million investment and appointing David Lazar as Co-CEO and Chairman.

Indaptus Therapeutics (INDP) surged 20% in premarket trading following the announcement of a $6 million securities purchase agreement with investor David E. Lazar, who was appointed Co-CEO and Chairman of the Board. The investment, comprising convertible preferred shares, includes 300,000 Series AA and 700,000 Series AAA shares, with conversion contingent on shareholder approval expected in Q1 2026. Lazar’s appointment and board reconstitution, including the addition of Avraham Ben-Tzvi, signal a strategic shift aimed at evaluating business opportunities for the company’s Decoy immunotherapy platform. The transaction, closed on December 23, 2025, underscores renewed investor confidence in Indaptus’ pipeline, which has demonstrated preclinical efficacy against cancers and viral infections. The news directly aligns with the stock’s upward movement, reflecting optimism over potential value-creation initiatives and leadership stability.